U-CHAMP: Urban Cardiovascular Health Assessment and Management Program
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by University of Calgary.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
University of Calgary
Collaborator:
University of Alberta
Information provided by:
University of Calgary
ClinicalTrials.gov Identifier:
NCT00626041
First received: January 14, 2008
Last updated: January 25, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
High blood pressure, elevated blood glucose and high cholesterol are related to the increased risk of stroke and heart disease. Many studies have shown that this risk can be significantly reduced by lowering blood pressure, blood glucose and cholesterol levels.
Through a collaborative effort between Calgary Safeway pharmacists and Calgary Health Region family physician PCN's, U-CHAMP will deliver a program to assist in the identification and management of people with elevated blood pressure, blood glucose and cholesterol and through this effort, reduce the risk of heart disease and stroke in the urban Calgary population aged 18-85 years.
| Condition | Intervention |
|---|---|
|
Cardiovascular Diseases Hypertension Hyperlipidemia Hyperglycemia |
Other: participant referral to primary care network physician |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Screening |
| Official Title: | U-CHAMP: Urban Cardiovascular Health Assessment and Management Program |
Resource links provided by NLM:
Further study details as provided by University of Calgary:
Primary Outcome Measures:
- Change in systolic blood pressure between baseline (average of visits one and two) and program end (final visit). [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Proportion of screened participants identified as being above blood pressure, cholesterol and blood glucose targets at visit two [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Proportion of participants that achieve published blood pressure (lipid and diabetes when appropriate) targets by program end [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Proportion of individuals that obtain both a baseline and end of program full lipid panel [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Change in Framingham Global Cardiovascular Risk score (in those participants that do not have known vascular disease or diabetes and have a recorded baseline and end-of-study full lipid panel). [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Proportion of individuals that have changes in drug therapy (new medication and/or dosage increase). [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 110 |
| Study Start Date: | February 2008 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
referral to primary care network for management of blood pressure, lipids and diabetes.
|
Other: participant referral to primary care network physician
blood pressure, cholesterol and hemoglobin A1c screening and management
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Adults 18-85 years
- Signed consent
Exclusion Criteria:
- None
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00626041
Contacts
| Contact: Donna M. Galvin, BScPharm | 403 938-1589 | dgalvin@ucalgary.ca |
Locations
| Canada, Alberta | |
| Calgary Safeway Pharmacy - Crowfoot Location | Recruiting |
| Calgary, Alberta, Canada, T3G 2L4 | |
| Contact: Rita Bowron, BScPharm 403-831-6987 | |
| Principal Investigator: Charlotte A Jones, PhD MD | |
| Coop Pharmacy - Crowfoot Location | Terminated |
| Calgary, Alberta, Canada, T3G 2L5 | |
Sponsors and Collaborators
University of Calgary
University of Alberta
Investigators
| Principal Investigator: | Charlotte Jones, PhD, MD | University of Calgary |
More Information
Additional Information:
Publications:
McLean DL, McAlister FA, Johnson JA, King KM, Jones CA, Tsuyuki RT. SCRIP-Hypertension program - Improving blood pressure management in patients with diabetes: The design of the SCRIP-HTN study. Canadian Pharmaceutical Journal 139: 1-4, 2006.
British Cardiac Society, British Hypertenion Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (5): 2005
| Responsible Party: | Dr. Charlotte Jones, University of Calgary |
| ClinicalTrials.gov Identifier: | NCT00626041 History of Changes |
| Other Study ID Numbers: | 03 71550000144 |
| Study First Received: | January 14, 2008 |
| Last Updated: | January 25, 2010 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University of Calgary:
|
Community pharmacies Primary care networks Global risk assessment Blood pressure screening |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Hyperglycemia Hyperlipidemias Hypertension Glucose Metabolism Disorders |
Metabolic Diseases Dyslipidemias Lipid Metabolism Disorders Vascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013